From the authors

European Respiratory Journal

Volumn 45, Issue 1, 2015, Pages 287-289

  Sotgiu, Giovanni ^a   Centis, Rosella ^b   D'Ambrosio, Lia ^b   Castiglia, Paolo ^a   Migliori, Giovanni Battista ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; RIFAMPICIN; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; BACTERIAL STRAIN; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LETTER; META ANALYSIS (TOPIC); MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROTOXICITY; NONHUMAN; OBSERVATIONAL STUDY; OPEN STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT RESPONSE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; MALE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ACETAMIDES; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; OXAZOLIDINONES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84920551094     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00135014     Document Type: Letter

References (11)

1. Sotgiu G, Centis R, D'Ambrosio L, et al. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. Eur Respir J 2013; 42: 288-290.
2. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.
3. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-1518.
4. Schön T, Juréen P, Chryssanthou E, et al. Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2011; 15: 502-509.
5. Hooker W. Physician and Patient. New York, Baker and Scribner, 1847. p. 219.
6. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010; 14: 382-390.
7. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391.
8. Alffenaar JW, van Altena R, Harmelink IM, et al. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 2010; 49: 559-565.
9. Koh WJ, Kang YR, Jeon K, et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother 2012; 67: 1503-1507.
10. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013; 42: 1449-1453.
11. Bolhuis MS, van Altena R, van Soolingen D, et al. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J 2013; 42: 1614-1621.